Literature DB >> 1399146

Immunotoxins directed against the high-molecular-weight melanoma-associated antigen. Identification of potent antibody-toxin combinations.

A Godal1, B Kumle, A Pihl, S Juell, O Fodstad.   

Abstract

To study factors influencing the cytotoxicity of immunotoxins (ITs), we compared the in vitro cytotoxicity of conjugates in which the plant toxin abrin and the bacterial toxin Pseudomonas exotoxin A (PE) were coupled by 2 different procedures to 2 MAbs, 9.2.27 and NR-ML-05, which bind to different epitopes on the melanoma-associated antigen p250. The individual target cell lines differed widely in sensitivity to the different ITs, as assessed by measurement of protein synthesis inhibition. The action of the ITs was highly specific, as the toxicity of abrin and PE conjugates was respectively 20-540 and 2,200-550,000 times higher in antigen-positive cell lines (FEMX, SESX, OHS) than in the antigen-negative line KPDX. The PE conjugates prepared with the 2 different MAbs differed in potency by factors of 16-126 in the target-cell lines, but were consistently more toxic than the abrin ITs. The results demonstrate that the cytotoxicity of ITs varies with the nature of both of its moieties and that optimal results require that toxins and MAbs be matched. Moreover, the 2 coupling procedures affected differentially the binding and potency of some ITs. Each of the 2 toxins was conjugated to a sheep anti-mouse antibody (SAM) and the toxicity of these 2 conjugates was tested in an indirect approach using 9.2.27 and NR-ML-05 as primary MAbs. The results showed that the indirect procedure would have correctly predicted the most potent antibody-toxin pair, indicating that the approach may be valid for selecting suitable combinations of MAbs and toxins for use as direct ITs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399146     DOI: 10.1002/ijc.2910520423

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  7 in total

1.  Immunotoxins: a promising treatment modality for metastatic melanoma?

Authors:  Karianne Risberg; Oystein Fodstad; Yvonne Andersson
Journal:  Ochsner J       Date:  2010

Review 2.  Targeted therapy for malignant melanoma.

Authors:  C K Brown; J M Kirkwood
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 3.  Antibody-based therapeutics for the treatment of human B cell malignancies.

Authors:  Sivasubramanian Baskar; Natarajan Muthusamy
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

4.  Targeting malignant B cells with an immunotoxin against ROR1.

Authors:  Sivasubramanian Baskar; Adrian Wiestner; Wyndham H Wilson; Ira Pastan; Christoph Rader
Journal:  MAbs       Date:  2012-04-26       Impact factor: 6.440

Review 5.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo.

Authors:  Y Andersson; O Engebraaten; Ø Fodstad
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

7.  Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.

Authors:  Y Andersson; O Engebraaten; S Juell; S Aamdal; P Brunsvig; Ø Fodstad; S Dueland
Journal:  Br J Cancer       Date:  2015-11-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.